The company receives manufacturing licenses for two additional poultry vaccines
Animal healthcare company, Hester Biosciences has reported Q1FY16 results. In Q1 of FY2016, the sales and net profit achieved are all time high. The net profit margin for Q1FY16 is 19.01 per cent of sales as against 16.20 per cent for FY15. The net profit in Q1FY16 is Rs 4.66 crore and the net sales is Rs 24.53 crores. EBITDA is reported at 33.34 per cent. Earnings per share are at Rs 5.48 for the quarter ended June 30, 2015 as compared to Rs 5.11 for the quarter ended on June 30, 2014.
Rajiv Gandhi, Chief Executive Officer and Managing Director, Hester Biosciences said, “The company got the manufacturing licences for two additional poultry vaccines Salmonella Live vaccine and IBH inactivated vaccine. These two vaccines put together would contribute Rs 2 crore sales in this financial year. Nepal plant is expected to go on stream in September 2015. The company foresees a higher growth rate in the coming quarters in this financial year.”
Comments are closed.